Skip to main content
SpringerLink
Log in

Diagnostiek, behandeling en nazorg van het basaalcelcarcinoom

  • Published:
Bijblijven

An Erratum to this article was published on 07 February 2017

Samenvatting

Het basaalcelcarcinoom (BCC) is de meest voorkomende vorm van kanker in Nederland (80% van alle huidkankers). Het aantal BCC’s is in ruim 35 jaar tijd enorm toegenomen en deze stijging zet door. Geschat wordt dat in 2020 de incidentie zelfs zal stijgen naar 234 per 100.000 persoonsjaren voor mannen en 226 per 100.000 persoonsjaren voor vrouwen. Vooral de vergrijzing in combinatie met de toegenomen hoeveelheid zonlichtexpositie vergroot het risico op het krijgen van een BCC. Dit artikel geeft een overzicht van de diagnostische procedures en de verschillende behandelmogelijkheden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figuur 1
Figuur 2
Figuur 3
Figuur 4
Figuur 5

Literatuur

  1. Evidence-based Richtlijn Basaalcelcarcinoom (Modulaire update 2015).

  2. Holterhues C, Vries E de, Louwman MW, Koljenovic S, Nijsten T. Incidence and trends of cutaneous malignancies in the Netherlands, 1989–2005. J Invest Dermatol. 2010;130(7):1807–12.

    Article  CAS  PubMed  Google Scholar 

  3. Flohil SC, Vries E de, Neumann HA, Coebergh JW, Nijsten T. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol. 2011;91(1):24–30.

    Article  PubMed  Google Scholar 

  4. Flohil SC, Seubring I, Rossum MM van, Coebergh JW, Vries E de, Nijsten T. Trends in Basal cell carcinoma incidence rates: a 37-year Dutch observational study. J Invest Dermatol. 2013;133(4):913–8.

    Article  CAS  PubMed  Google Scholar 

  5. Flohil SC, Tiel S van, Koljenovic S, Jaanen-van der Sanden G, Overbeek LI, Vries E de, Nijsten T. Frequency of non-histologically diagnosed basal cell carcinomas in daily Dutch practice. J Eur Acad Dermatol Venereol. 2013;27(7):907–11.

    Article  CAS  PubMed  Google Scholar 

  6. Vries E de, Nijsten T, Louwman MW, Coebergh JW. Skin cancer epidemic in the Netherlands. Ned Tijdschr Geneeskd. 2009;153:A768.

    PubMed  Google Scholar 

  7. Lo JS, Snow SN, Reizner GT, Mohs FE, Larson PO, Hruza GJ. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol. 1991;24(5 Pt 1):715–9.

    Article  CAS  PubMed  Google Scholar 

  8. Trakatelli M, Morton CA, Nagore E, Ulrich C, Marmo V del, Peris K, Basset-Seguin N, European Dermatology Forum. Update of the guideline on basal cell carcinoma. Eur J Dermatol. 2014;24(3):312–29.

    PubMed  Google Scholar 

  9. Roozeboom MH, Mosterd K, Winnepenninckx VJ, Nelemans PJ, Kelleners-Smeets NW. Agreement between histological subtype on punch biopsy and surgical excision in primary basal cell carcinoma. J Eur Acad Dermatol Venereol. 2013;27:894–8.

    Article  CAS  PubMed  Google Scholar 

  10. Russell EB, Carrington PR, Smoller BR. Basal cell carcinoma: a comparison of shave biopsy versus punch biopsy techniques in subtype diagnosis. J Am Acad Dermatol. 1999;41:69–71.

    Article  CAS  PubMed  Google Scholar 

  11. Wolberink EA, Pasch MC, Zeiler M, Erp PE van, Gerritsen MJ. High discordance between punch biopsy and excision in establishing basal cell carcinoma subtype: analysis of 500 cases. J Eur Acad Dermatol Venereol. 2013;27:985–9.

    Article  CAS  PubMed  Google Scholar 

  12. Altamura D, Menzies SW, Argenziano G, Zalaudek I, Soyer HP, Sera F, et al. Dermatoscopy of basal cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis. J Am Acad Dermatol. 2010;62(1):67–75.

    Article  PubMed  Google Scholar 

  13. Mosterd K, Thissen MR, Nelemans P, Kelleners-Smeets NW, Janssen RL, Broekhof KG, et al. Fractionated 5‑aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol. 2008;159(4):864–70.

    Article  CAS  PubMed  Google Scholar 

  14. Szeimies RM, Ibbotson S, Murrell DF, Rubel D, Frambach Y, Berker D de, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8–20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol. 2008;22(11):1302–11.

    Article  CAS  PubMed  Google Scholar 

  15. Rhodes LE, Rie MA de, Leifsdottir R, Yu RC, Bachmann I, Goulden V, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143(9):1131–6.

    Article  CAS  PubMed  Google Scholar 

  16. Rhodes LE, Rie M de, Enström Y, Groves R, Morken T, Goulden V, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol. 2004;140(1):17–23.

    Article  CAS  PubMed  Google Scholar 

  17. Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PS, Williams HC. Surgical excision versus imiquimod 5 % cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(1):96–105.

    Article  CAS  PubMed  Google Scholar 

  18. Loo E van, Mosterd K, Krekels GA, Roozeboom MH, Ostertag JU, Dirksen CD, et al. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer 2014;50(17):3011–20.

    Article  PubMed  Google Scholar 

  19. Chren MM, Torres JS, Stuart SE, Bertenthal D, Labrador RJ, Boscardin WJ. Recurrence after treatment of nonmelanoma skin cancer: a prospective cohort study. Arch Dermatol. 2011;147(5):540–6.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, et al. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5‑years’ follow-up. Lancet Oncol. 2008;9(12):1149–56.

    Article  PubMed  Google Scholar 

  21. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5‑year follow-up. J Am Acad Dermatol. 2005;53(3):4–7.

    Google Scholar 

  22. Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation. J Dermatol Surg Oncol. 1991;17(9):720–6.

    Article  CAS  PubMed  Google Scholar 

  23. Kopf AW, Bart RS, Schrager D, Lazar M, Popkin GL. Curettage-electrodesiccation treatment of basal cell carcinomas. Arch Dermatol. 1977;113(4):439–43.

    Article  CAS  PubMed  Google Scholar 

  24. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 2006;6(7):535–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Arits AH, Mosterd K, Essers BA, Spoorenberg E, Sommer A, Rooij MJ de, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14(7):647–54.

    Article  CAS  PubMed  Google Scholar 

  26. Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-Smeets NW. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. Br J Dermatol. 2012;167:733–56.

    Article  CAS  PubMed  Google Scholar 

  27. Roozeboom MH, Arits AH, Mosterd K, Sommer A, Essers BA, Rooij MJ de, et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. J Invest Dermatol. 2016;136(8):1568–74.

    Article  CAS  PubMed  Google Scholar 

  28. Krema H, Herrmann E, Albert-Green A, Payne D, Laperriere N, Chung C. Orthovoltage radiotherapy in the management of medial canthal basal cell carcinoma. Br J Ophthalmol. 2013;97(6):730–4.

    Article  PubMed  Google Scholar 

  29. Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys. 2004;60(2):406–11.

    Article  PubMed  Google Scholar 

  30. Khan L, Choo R, Breen D, Assaad D, Fialkov J, Antonyshyn O, et al. Recommendations for CTV margins in radiotherapy planning for non melanoma skin cancer. Radiother Oncol. 2012;104(2):263–6.

    Article  PubMed  Google Scholar 

  31. Cognetta AB, Howard BM, Heaton HP, Stoddard ER, Hong HG, Green WH. Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. J Am Acad Dermatol. 2012;67(6):1235–41.

    Article  PubMed  Google Scholar 

  32. Olschewski T, Bajor K, Lang B, Lang E, Seegenschmiedt MH. Radiotherapy of basal cell carcinoma of the face and head: importance of low dose per fraction on long-term outcome. J Dtsch Dermatol Ges. 2006;4(2):124–30.

    Article  PubMed  Google Scholar 

  33. Silva JJ, Tsang RW, Panzarella T, Levin W, Wells W. Results of radiotherapy for epithelial skin cancer of the pinna: the Princess Margaret Hospital experience, 1982–1993. Int J Radiat Oncol Biol Phys. 2000;47(2):451–9.

    Article  CAS  PubMed  Google Scholar 

  34. Van Hezewijk M, Creutzberg CL, Putter H, Chin A, Schneider I, Hoogeveen M, et al. Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: analysis of 434 cases. Radiother Oncol. 2010;95(2):245–9.

    Article  PubMed  Google Scholar 

  35. Zagrodnik B, Kempf W, Seifert B, Muller B, Burg G, Urosevic M, et al. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. Cancer 2003;98(12):2708–14.

    Article  PubMed  Google Scholar 

  36. Duinkerken CW, Lohuis PJ, Heemsbergen WD, Zupan-Kajcovski B, Navran A, Hamming-Vrieze O, et al. Orthovoltage for basal cell carcinoma of the head and neck: excellent local control and low toxicity profile. Laryngoscope 2016;126(8):1796–802.

    Article  PubMed  Google Scholar 

  37. Bessems P. The cryosurgical open-cone-spray method. Proefschrift. Maastricht: Maastricht University; 1989.

    Google Scholar 

  38. Wang I, Bendsoe N, Klinteberg CA, Enejder AM, Andersson-Engels S, Svanberg S, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol. 2001;144(4):832–40.

    Article  CAS  PubMed  Google Scholar 

  39. Hall VL, Leppard BJ, McGill J, Kesseler ME, White JE, Goodwin P. Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol. 1986;37(1):33–4.

    Article  CAS  PubMed  Google Scholar 

  40. Bath-Hextall F, Bong J, Perkins W, Williams H. Interventions for basal cell carcinoma of the skin: systematic review. BMJ. 2004;329(7468):705.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5 % cream. J Am Acad Dermatol. 1999;41(6):1002–7.

    Article  CAS  PubMed  Google Scholar 

  42. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722–33.

    Article  PubMed  Google Scholar 

  43. Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, et al. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002;47(3):390–8.

    Article  PubMed  Google Scholar 

  44. Gollnick H, Barona CG, Frank RG, Ruzicka T, Megahed M, Tebbs V, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5 % cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol. 2005;15(5):374–81.

    CAS  PubMed  Google Scholar 

  45. Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, et al. Imiquimod 5 % cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 2001;44(5):807–13.

    Article  CAS  PubMed  Google Scholar 

  46. Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrandiz C, Garcia DA, et al. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152(5):939–47.

    Article  CAS  PubMed  Google Scholar 

  47. Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A, et al. Efficacy of topical 5 % imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol. 2002;138(9):1165–71.

    Article  CAS  PubMed  Google Scholar 

  48. Sterry W, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K, et al. Imiquimod 5 % cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002;147(6):1227–36.

    Article  CAS  PubMed  Google Scholar 

  49. Dreier J, Felderer L, Barysch M, Rozati S, Dummer R. Basal cell carcinoma: a paradigm for targeted therapies. Expert Opin Pharmacother. 2013;14(10):1307–18.

    Article  CAS  PubMed  Google Scholar 

  50. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164–72.

    Article  Google Scholar 

  51. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008;8(10):743–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008 Oct;8(10):743–54.SmPC Erivedge, 22 mei 2014.

  53. Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70:60–9.

    Article  CAS  PubMed  Google Scholar 

  54. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000;136(12):1524–30.

    Article  CAS  PubMed  Google Scholar 

  56. Iersel CA van, Velden HV van de, Kusters CD, Spauwen PH, Blokx WA, Kiemeney LA, Gerritsen MJ. Prognostic factors for a subsequent basal cell carcinoma: implications for follow-up. Br J Dermatol. 2005;153(5):1078–80.

    Article  PubMed  Google Scholar 

  57. Flohil SC, Leest RJ van der, Arends LR, Vries E de, Nijsten T. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer 2013;49(10):2365–75.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. afdeling Dermatologie, Maastricht Universitair Medisch Centrum, Maastricht, Nederland

    Esther Burkink &  Nicole W. J. Kelleners-Smeets

Authors
  1. Esther Burkink
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicole W. J. Kelleners-Smeets
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Esther Burkink.

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/s12414-017-0219-9.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Burkink, E., Kelleners-Smeets, N.W.J. Diagnostiek, behandeling en nazorg van het basaalcelcarcinoom. Bijblijven 33, 114–128 (2017). https://doi.org/10.1007/s12414-016-0204-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12414-016-0204-8

Search

Navigation